Warfarin is a widely used anticoagulant with a narrow therapeutic index and large interpatient variability in the dose required to achieve target anticoagulation.
The aim of this study was to investigate the impact of FVII polymorphism (G10976A, rs6046) on international normalized ratio (INR) values changes and dose warfarine.
Materials and Methods. The study included 138 patients with heart valve replacement (64.5% male, 35.5% women, average age (51.1±1.2) years). 98 patients received warfarine treatment from initial dose of 5 mg/day. Subgroup A (n=22) — patients with INR values out of therapeutic range and subgroup B (n=76) patients with INR values from 2.5 to 3.5.
For determination of polymorphic variant G10976A of FVII gene the method of PCR-RFLP has been used.
Results. The frequencies of 10976GG, 10976GA and 10976AA genotype among the patients group were 81.16%, 18.12% та 0.72%, respectively. The significant differences in subgroups A and B for G10976A polymorphic variant were not found. The mean daily dose of warfarine was (3.50±0.17) mg in patients with 10976GG genotype and (2.88±0.38) mg with 10976GA genotype. The significant differences were not found for warfarine dose with G10976A polymorphic variant of FVII gene.
Conclusions. We have not found effect of FVII polymorphism on INR values changes and warfarine dose in patients with heart valve replacement.